Abstract:The discovery of immune checkpoints has been well known to provide novel clues for cancer treatments. Immunotherapy against the programmed cell death protein-1 (PD-1) /programmed death-ligand-1 (PD-L1), one of the most popular auxiliary treatments in recent years, has been applied in various tumor treatments, including non-small cell lung cancer (NSCLC). However, inevitable issues such as side effects and drug resistance emerge following the use of immune checkpoint inhibitors. The PI3K/AKT/mTOR pathway may participate in the regulation of PD-L1 expression. Abnormal PI3K/AKT/mTOR pathway activation results in increased PD-L1 protein translation, whereas PD-L1 overexpression can activate the PI3K/AKT/mTOR pathway inversely. Via downstream proteins, including 4E-BP1, STAT3, NF-κB, c-MYC, and AMPK in aberrant energy status, the PI3K/AKT/mTOR pathway can regulate PD-L1 post-transcription and translation. Besides, the regulation of the PI3K pathway by the PD-1/PD-L1 axis involves both tumor cells and the tumor immune microenvironment. Inhibitors targeting the PD-1/PD-L1 have been successfully applied in the treatment of gastrointestinal cancer and breast cancer. Meanwhile, drug resistance from alternative pathway activation also evidently affects clinical progress. To achieve a better therapeutic effect and quality of survival, the combination of multiple treatment modalities presents great research value. Here we reviewed the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in the progression and treatment of NSCLC and summarized its clinical implications. The intracellular interactions between PD-1/PD-L1 and the PI3K/AKT/mTOR pathway indicate that PD-1/PD-L1 inhibitors have a wide range of potential applications. And we presented the mechanism for combining therapy with monoclonal antibody PD-1/PD-L1 and PI3K/AKT/mTOR inhibitors in this review, to broaden the therapies for NSCLC.

Progress about Relationship with PI3K/Akt Signaling Pathway and tumor chemoresistance

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Targeting PI3K/Akt signal transduction for cancer therapy

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Role of PI3K/Akt Signaling Pathway in Tumor Progress and Treatment

Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance

The Role of Phosphatidylinositol 3-Kinase Signaling Pathways in Pancreatic Cancer

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance

PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma

Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Suppression of Esophageal Tumor Growth and Chemoresistance by Directly Targeting the Pi3k/Akt Pathway

Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy

[Correlation of PI3K-Akt Signal Pathway to Apoptosis of Tumor Cells].

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells

PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer.

Activity of PI3'K/Akt/FKHRL1 Signaling Pathway Induced by Doxorubicin Confer Chemoresistance in Gastric Cancer Cell

The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma